Cho dg44

Manufactured by Thermo Fisher Scientific

Sourced in United States

The CHO-DG44 is a cell line derived from Chinese Hamster Ovary (CHO) cells. It is a subclone of the DG44 cell line, which is commonly used for the production of recombinant proteins in cell culture.

Automatically generated - may contain errors

Lab products found in correlation

Freestyle max reagent, by Thermo Fisher Scientific (2 mentions) Pluronic f 68, by Thermo Fisher Scientific (2 mentions) Cd dg44 medium, by Thermo Fisher Scientific (2 mentions) Cd opticho, by Thermo Fisher Scientific (2 mentions) L glutamine, by Thermo Fisher Scientific (2 mentions) Hitrap rprotein a ff column, by GE Healthcare (1 mentions) High performance liquid chromatography (hplc), by Waters Corporation (1 mentions) Fetal calf serum (fcs), by Atlanta Biologicals (1 mentions) Nci h446, by American Type Culture Collection (1 mentions) C1498, by American Type Culture Collection (1 mentions) Hepa1 6, by American Type Culture Collection (1 mentions) E g7 ova, by American Type Culture Collection (1 mentions) Soybean peptone, by Merck Group (1 mentions) Erlenmeyer flask, by Corning (1 mentions) Bioprofile 100 plus, by Nova Biomedical (1 mentions) Vi cell xr, by Beckman Coulter (1 mentions) Cho k1, by American Type Culture Collection (1 mentions)

Spelling variants of this product

CHO DG44 cells (5 citations)

6 protocols using cho dg44

Engineered IgE Trap Protein

Check if the same lab product or an alternative is used in the 5 most similar protocols

IgE_TRAP was constructed by linking the C-terminus of the FcεRIα extracellular domain (25th−205th; 181 amino acids) to the N-terminus of an IgD (133rd−170th; 38 amino acids)/IgG4 (121st−327th; 207 amino acids) hybrid Fc domain via a linker. The protein was expressed in dihydrofolate reductase-deficient CHO DG44 (Thermo Fischer, USA) cells and transferred with the α−2,6-sialyltransferase gene. IgE_TRAP was purified using a HiTrap rProtein A FF column (GE Healthcare, USA) and analyzed by SDS-PAGE under reducing and non-reducing conditions. Moreover, IgE_TRAP was further purified into two fractions according to the degree of its negative charge using a HiScreen Q Sepharose FF (GE Healthcare, USA) anion exchange chromatography column. The extent of sialylation of IgE_TRAP was confirmed in IEF gel or analyzed by HPLC (Waters, USA). Additionally, IgE_TRAP with superior ability to induce IgG1 Fc-mediated side effects was made by referring to the previous report^{43 (link),44 (link)}. This protein has a modified IgG1-Fc (T250Q/S298A/K334A/M428L) instead of the IgD/IgG4 hybrid Fc and is referred here as IgE_TRAP-IgG1M2.

An S.B., Yang B.G., Jang G., Kim D.Y., Kim J., Oh S.M., Oh N., Lee S., Moon J.Y., Kim J.A., Kim J.H., Song Y.J., Hyun H.W., Kim J., Lee K., Lee D., Kwak M.J., Kim B.K., Park Y.K., Hong C.P., Kim J.H., Lim H.S., Ryu M.S., Jin H.T., Lee S.W., Chang Y.S., Park H.S., Sung Y.C, & Jang M.H. (2022). Combined IgE neutralization and Bifidobacterium longum supplementation reduces the allergic response in models of food allergy. Nature Communications, 13, 5669.

+ Open protocol

+ Expand

Cell Culture of Lung Carcinoma, MDCK, and CHO Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols

Human lung carcinoma A549 cells were obtained from ATCC (#CRM-CCL-185) (Manassas, VA, USA). Madin-Darby canine kidney (MDCK) cells and the Chinese hamster ovary (CHO) cell-line CHO-DG44 (DHFR-/-), which were originally acquired from ATCC, were kindly provided by Dr. Jiao, CDC Jiangsu, China. A549 and MDCK cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal calf serum (FCS; Atlanta Biologicals, Flowery Branch, GA, USA). CHO-DG44 (DHFR-/-) cells were cultured in CHO DG44 cell medium (Thermo Fisher Scientific, USA). All the cell lines were grown at 37°C in a 5% CO₂ atmosphere.

Jin Q., Yao Z., Liu F., Di Y., Gao J, & Zhang X. (2022). The protective effect of a combination of human intracellular and extracellular antibodies against the highly pathogenic avian influenza H5N1 virus. Human Vaccines & Immunotherapeutics, 18(1), 2035118.

+ Open protocol

+ Expand

Engineered Tumor Cell Lines for Immunotherapy

Check if the same lab product or an alternative is used in the 5 most similar protocols

C1498, E.G7-OVA, Hepa1-6, LLC1, and NCI-H446 were purchased from the ATCC. Colon38 was obtained from NIH (Bethesda, MD). GPC3 and/or chicken ovalbumin (OVA)-overexpressing Hepa1-6/ hGPC3 (29), LLC1/OVA/hGPC3, LLC1/hGPC3, and LLC1/OVA cells were established by transfecting GPC3 and/or OVA-expressing plasmids into parental cells to enhance the immunogenicity of each tumor, and also to allow us to test the combination of STA551 with a TRAB against GPC3. Human FcγRIIb-expressing CHOk1 cells (CHOk1/human FcγRIIb cells) were purchased from Promega, and CHO-DG44 from Thermo Fisher Scientific. Mouse FcγRIIboverexpressing CHO, human FcγRIIa-overexpressing CHO, and human FcγRIIb-overexpressing CHO were established by transfecting mouse FcγRIIb-expressing plasmids, H allotype of human FcγRIIaexpressing plasmids, or human FcγRIIb-expressing plasmids into parental CHO-DG44 cells. Human CD137-overexpressing CHO was established by transfecting human CD137-expressing plasmids into parental CHO-DG44 cells.

Kamata-Sakurai M., Narita Y., Hori Y., Nemoto T., Uchikawa R., Honda M., Hironiwa N., Taniguchi K., Shida-Kawazoe M., Metsugi S., Miyazaki T., Wada N.A., Ohte Y., Shimizu S., Mikami H., Tachibana T., Ono N., Adachi K., Sakiyama T., Matsushita T., Kadono S., Komatsu S.I., Sakamoto A., Horikawa S., Hirako A., Hamada K., Naoi S., Savory N., Satoh Y., Sato M., Noguchi Y., Shinozuka J., Kuroi H., Ito A., Wakabayashi T., Kamimura M., Isomura F., Tomii Y., Sawada N., Kato A., Ueda O., Nakanishi Y., Endo M., Jishage K.I., Kawabe Y., Kitazawa T, & Igawa T. (2021). Antibody to CD137 Activated by Extracellular Adenosine Triphosphate Is Tumor Selective and Broadly Effective In Vivo without Systemic Immune Activation. Cancer discovery, 11(1).

+ Open protocol

+ Expand

Suspension CHO Cell Transfection and Amplification

Check if the same lab product or an alternative is used in the 5 most similar protocols

Suspension CHO (CHO DG44, Gibco, hereinafter termed susCHO) cells were cultured in CD DG44 medium (Gibco) supplemented with 8 mM l-glutamine (Gibco) and 0.18% Pluronic® F-68 prior to transfection. Transfection was performed by combining 18 μg AhdI-linearized plasmid pOpti_IL2_S377-588-Fc and 15 μL of FreeStyle™ MAX Reagent (Invitrogen) in 1.2 mL OptiPRO SFM and incubated at room temperature for 10 min, followed by dropwise addition to 1.5 × 10⁷ cells in 30 mL of CD DG44 culture medium (non-selective) according to the manufacturer’s instructions. After 48 h, cells were transferred to selective medium (CD OptiCHO, Invitrogen), supplemented with 8 mM l-glutamine and 0.18% Pluronic® F-68 (Gibco), and cultivated until cell viability reached 90%. After selection, stably transfected susCHO cells underwent DNA amplification by gradually increasing MTX concentration (20–5000 nM) in selective medium. All suspension culture flasks were maintained in a humidified incubator, 37 °C/8% CO₂ on a shaker, at a constant rotation rate of 135 rpm.

Nyon M.P., Du L., Tseng C.T., Seid C.A., Pollet J., Naceanceno K.S., Agrawal A., Algaissi A., Peng B.H., Tai W., Jiang S., Bottazzi M.E., Strych U, & Hotez P.J. (2018). Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine, 36(14), 1853-1862.

+ Open protocol

+ Expand

Suspension CHO Cell Transfection and Amplification

Check if the same lab product or an alternative is used in the 5 most similar protocols

Suspension CHO (CHO DG44, Gibco, hereinafter termed susCHO) cells were cultured in CD DG44 medium (Gibco) supplemented with 8 mM L-glutamine (Gibco) and 0.18% Pluronic^® F-68 prior to transfection. Transfection was performed by combining 18 μg AhdI-linearized plasmid pOpti_IL2_S377-588-Fc and 15 μL of FreeStyle^™ MAX Reagent (Invitrogen) in 1.2 mL OptiPRO SFM and incubated at room temperature for 10 minutes, followed by dropwise addition to 1.5×10⁷ cells in 30 mL of CD DG44 culture medium (non-selective) according to the manufacturer’s instructions. After 48 hours, cells were transferred to selective medium (CD OptiCHO, Invitrogen), supplemented with 8 mM L-glutamine and 0.18% Pluronic^® F-68 (Gibco), and cultivated until cell viability reached 90%. After selection, stably transfected susCHO cells underwent DNA amplification by gradually increasing MTX concentration (20–5,000 nM) in selective medium. All suspension culture flasks were maintained in a humidified incubator, 37°C/8% CO₂ on a shaker, at a constant rotation rate of 135 rpm.

+ Open protocol

+ Expand

Comparative Growth of CHO Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols

CHO-K1 (ATCC No. CCL-61, American Type Culture Collection, USA), CHO-DXB11 (ATCC No. CRL-9096, American Type Culture Collection) and CHO-DG44 (Gibco™ catalog number 12609-012, Invitrogen, USA) previously adapted to serum free suspension culture were propagated in a DMEM/F12-based protein free chemically defined medium (PFCDM) supplemented with Soybean peptone (Catalog number P0521, Sigma-Aldrich, USA) and HT supplement (Gibco™ catalog number 11067-030, ThermoFisher Scientific, USA). To compare cell growth over 6 days, all three cell lines were cultivated in batch mode by seeding 2×10 5 cells/mL into orbitally agitated disposable Erlenmeyer flasks (Corning, USA) in duplicates. Replicate shake flasks were cultivated similarly and harvested at Day 2 for the various -omics analyses. Cell density and viability were measured daily by the trypan blue dye exclusion method using Vi-Cell XR (Beckman Coulter, USA). Glucose, lactate, ammonium, glutamine and glutamate concentrations in the culture supernatant were measured daily using BioProfile 100 Plus (Nova Biomedical, USA).

Lakshmanan M., Kok Y.J., Lee A.P., Kyriakopoulos S., Lim H.L., Teo G., Poh S.L., Tang W.Q., Hong J., Tan A.H., Bi X., Ho Y.S., Zhang P., Ng S.K, & Lee D.Y. (2019). Multi-omics profiling of CHO parental hosts reveals cell line-specific variations in bioprocessing traits. Biotechnology and bioengineering, 116(9).

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!